Fintel reports that on December 23, 2024, Brookline Capital initiated coverage of Exelixis (NasdaqGS:EXEL) with a Buy recommendation.
Analyst Price Forecast Suggests 0.48% Downside
As of December 3, 2024, the average one-year price target for Exelixis is $33.32/share. The forecasts range from a low of $23.23 to a high of $40.95. The average price target represents a decrease of 0.48% from its latest reported closing price of $33.48 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Exelixis is 2,076MM, a decrease of 0.27%. The projected annual non-GAAP EPS is 1.31.
What is the Fund Sentiment?
There are 1,008 funds or institutions reporting positions in Exelixis. This is an increase of 48 owner(s) or 5.00% in the last quarter. Average portfolio weight of all funds dedicated to EXEL is 0.33%, an increase of 2.57%. Total shares owned by institutions increased in the last three months by 8.55% to 298,918K shares. 
The put/call ratio of EXEL is 0.65, indicating a bullish outlook.
What are Other Shareholders Doing?
Farallon Capital Management holds 25,410K shares representing 8.90% ownership of the company. In its prior filing, the firm reported owning 27,102K shares , representing a decrease of 6.66%. The firm increased its portfolio allocation in EXEL by 12.28% over the last quarter.
Renaissance Technologies holds 15,360K shares representing 5.38% ownership of the company. In its prior filing, the firm reported owning 15,163K shares , representing an increase of 1.28%. The firm increased its portfolio allocation in EXEL by 3.72% over the last quarter.
IJH - iShares Core S&P Mid-Cap ETF holds 8,917K shares representing 3.12% ownership of the company. In its prior filing, the firm reported owning 9,061K shares , representing a decrease of 1.61%. The firm increased its portfolio allocation in EXEL by 3.81% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,635K shares representing 3.02% ownership of the company. In its prior filing, the firm reported owning 8,845K shares , representing a decrease of 2.44%. The firm increased its portfolio allocation in EXEL by 5.89% over the last quarter.
Lsv Asset Management holds 8,102K shares representing 2.84% ownership of the company. In its prior filing, the firm reported owning 5,764K shares , representing an increase of 28.86%. The firm increased its portfolio allocation in EXEL by 58.82% over the last quarter.
Exelixis Background Information
(This description is provided by the company.)
Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, it established a broad drug discovery and development platform that has served as the foundation for its continued efforts to bring new cancer therapies to patients in need. Its discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and it has entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from its marketed products and collaborations, it is committed to prudently reinvesting in its business to maximize the potential of its pipeline. It is supplementing its existing therapeutic assets with targeted business development activities and internal drug discovery - all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor's (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. In November 2020, the company was named to Fortune's 100 Fastest-Growing Companies list for the first time, ranking 17th overall and the third-highest biopharmaceutical company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
